Cellebrite DI Sees Unusually Large Options Volume (NASDAQ:CLBT)

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of some unusual options trading activity on Tuesday. Investors acquired 20,138 call options on the company. This represents an increase of approximately 2,374% compared to the average daily volume of 814 call options.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CMO David Gee sold 4,323 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $11.36, for a total transaction of $49,109.28. Following the sale, the chief marketing officer directly owned 135,281 shares in the company, valued at $1,536,792.16. This represents a 3.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CRO Marcus Jewell sold 12,562 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.24, for a total transaction of $141,196.88. Following the completion of the transaction, the executive directly owned 427,128 shares of the company’s stock, valued at $4,800,918.72. This represents a 2.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 196,870 shares of company stock worth $2,797,143. 5.70% of the stock is currently owned by company insiders.

Institutional Trading of Cellebrite DI

Hedge funds have recently added to or reduced their stakes in the stock. Elevation Wealth Partners LLC acquired a new stake in shares of Cellebrite DI during the second quarter worth $44,000. PNC Financial Services Group Inc. raised its position in Cellebrite DI by 59.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock worth $103,000 after buying an additional 2,785 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Cellebrite DI by 91.1% during the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock worth $105,000 after acquiring an additional 3,626 shares during the period. Quantinno Capital Management LP purchased a new position in Cellebrite DI during the first quarter worth about $150,000. Finally, Ground Swell Capital LLC purchased a new position in Cellebrite DI during the third quarter worth about $128,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CLBT shares. JPMorgan Chase & Co. decreased their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. DA Davidson reaffirmed a “buy” rating and issued a $15.00 price target on shares of Cellebrite DI in a research report on Tuesday, September 15th. Weiss Ratings lowered Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 27th. Lake Street Capital lowered their price objective on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Needham & Company LLC lowered their price objective on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.70.

Cellebrite DI Price Performance

Shares of CLBT traded down $0.21 during mid-day trading on Tuesday, reaching $12.48. 1,492,180 shares of the company’s stock were exchanged, compared to its average volume of 2,236,020. The stock has a market capitalization of $3.11 billion, a PE ratio of 56.70, a price-to-earnings-growth ratio of 1.91 and a beta of 1.06. The business’s fifty day simple moving average is $11.59 and its 200-day simple moving average is $13.30. Cellebrite DI has a 52-week low of $9.58 and a 52-week high of $19.98.

About Cellebrite DI

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems.

The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian.